Related Experiment Videos
[Percutaneous microwave coagulation therapy for hepatocellular carcinoma]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 24, 1999
Summary
Percutaneous microwave coagulation therapy (PMCT) shows survival benefits for hepatocellular carcinoma (HCC) patients. However, local recurrence is common, especially in larger or poorly differentiated tumors, suggesting careful patient selection for PMCT is crucial.
Area of Science:
- Hepatobiliary Surgery
- Interventional Radiology
- Oncology
Context:
- Hepatocellular carcinoma (HCC) presents a significant global health challenge.
- Percutaneous microwave coagulation therapy (PMCT) is an ablative technique used for HCC treatment.
- Evaluating the efficacy and limitations of PMCT in primary and recurrent HCC is essential.
Purpose:
- To assess the survival rates and local recurrence patterns of patients with primary and recurrent HCC treated with PMCT.
- To identify factors influencing local recurrence after PMCT for HCC.
- To establish optimal patient selection criteria for PMCT in HCC management.
Summary:
- This study evaluated 34 HCC patients (18 primary, 16 recurrent) treated with PMCT.
- Survival rates were comparable between primary and recurrent HCC groups, but local recurrence occurred in approximately 50% of patients.
- Local recurrence was associated with larger tumor size and poorly differentiated HCC. PMCT is recommended for well-differentiated HCC < 2 cm or in combination therapy for specific patient subgroups.
Impact:
- Findings suggest PMCT is effective but requires careful patient selection based on tumor differentiation and size.
- Identifies limitations of PMCT, particularly concerning local control in advanced HCC.
- Provides evidence-based recommendations for optimizing PMCT use in HCC treatment algorithms, potentially improving patient outcomes.